PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ventus Therapeutics

Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers

Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers

April 18, 2024

Ventus Entered into an Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program to Treat Cardiometabolic Diseases

Ventus Entered into an Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program to Treat Cardiome...

September 29, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us